TY - JOUR
T1 - NF-κB-driven miR-34a impairs Treg/Th17 balance via targeting Foxp3
AU - Xie, Mengxiao
AU - Wang, Jingzhe
AU - Gong, Wen
AU - Xu, Huiling
AU - Pan, Xiaoyuan
AU - Chen, Yunpeng
AU - Ru, Songwei
AU - Wang, Hui
AU - Chen, Xiaodan
AU - Zhao, Yi
AU - Li, Jing
AU - Yin, Qing
AU - Xia, Sheng
AU - Zhou, Xiaoming
AU - Liu, Xia
AU - Shao, Qixiang
N1 - Funding Information:
Our research was supported by the Chinese National Natural Science Foundation Grant (Grant No. 81273202 , 81671541 , 31400773 ), Clinical Medicine Science & Technology Project of Jiangsu province of China (Grant No. BL2013024 ), Key Research and Development Programs Social Development Project of Science and Technology Commission Foundation of Jiangsu Province (Grant No. BE2016721 ), Science and Technology Support Program (Social Development) of Zhenjiang (Grant No. SH2015055 ).
Funding Information:
Our research was supported by the Chinese National Natural Science Foundation Grant (Grant No. 81273202, 81671541, 31400773), Clinical Medicine Science & Technology Project of Jiangsu province of China (Grant No. BL2013024), Key Research and Development Programs Social Development Project of Science and Technology Commission Foundation of Jiangsu Province (Grant No. BE2016721), Science and Technology Support Program (Social Development) of Zhenjiang (Grant No. SH2015055). We would like to thank Prof. Yu Zhang (Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, P.R. China) and Prof. Bin Li (Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, P.R. China) for advice and help. We thank Prof. David Baltimore (California Institute of Technology, CA, USA), Prof. Zhihong Zhang and Prof. Qingming Luo (Huazhong University of Science and Technology), Dr. Huan Qiao (Vanderbilt University Medical Center, OH, USA.), Prof. Yongchang Chen (School of Medicine, Jiangsu University, P.R. China), Prof. Zhiqiang Xiao (Xiangya Hospital, Central South University, P.R. China) and Prof. Jinping Zhang (Suchow University) for the generous gifts of the plasmids and the miR-34a transgenic mice. We thank Dr. Yu Tang (Department of Rheumatology, The Affiliated Hospital of Jiangsu University) and Dr. Hui Zhang (Department of Laboratory Medicine, Affiliated Hospital of Jiangsu University) for the collection of whole blood samples from RA and SLE patients. We also thank all the patients and healthy donors who took part in this study. It was impossible to do this work without their help.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/8
Y1 - 2019/8
N2 - The subset of regulatory T (Treg) cells, with its specific transcription Foxp3, is a unique cell type for the maintenance of immune homeostasis by controlling effector T (Teff) cell responses. Although it is common that a defect in Treg cells with Treg/Teff disorder causes autoimmune diseases; however, the precise mechanisms are not thoroughly revealed. Here, we report that miR-34a could attenuate human and murine Foxp3 gene expression via targeting their 3′ untranslated regions (3′ UTR). The human miR-34a, increased in peripheral blood mononuclear cells (PBMCs) and CD4+ T cells from rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) patients, displayed a positive correlation with some serum markers of inflammation including rheumatoid factor (RF), anti-streptolysin antibody (ASO), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) as well as Th17 signature gene RORγt, but inversely correlated with the mRNA expression levels of FOXP3. In addition, murine miR-34a levels were downregulated in TGF-β-induced Treg cells but upregulated in Th17 cells induced in vitro compared to activated CD4+ T cells. It has also been demonstrated that elevated miR-34a disrupting Treg/Th17 balance in vivo contributed to the progress of pathogenesis of collagen induced arthritis (CIA) mice. Furthermore, IL-6 and TNF-α were responsible for the upregulation of miR-34a and downregulation of Foxp3, which was reverted by the addition of NF-κB/p65 inhibitor BAY11-7082, thus indicating that NF-κB/p65 inhibited Foxp3 expression in an miR-34a-dependent manner. Finally, IL-6 or TNF-α-activated p65 could bind to the miR-34a promotor and enhance its activity, resulting in upregulation of its transcription. Taken together, we show that NF-κB activated by inflammatory cytokines, such as IL-6 and TNF-α, ameliorates Foxp3 levels via regulating miR-34a expression, which provides a new mechanistic and therapeutic insight into the ongoing of autoimmune diseases.
AB - The subset of regulatory T (Treg) cells, with its specific transcription Foxp3, is a unique cell type for the maintenance of immune homeostasis by controlling effector T (Teff) cell responses. Although it is common that a defect in Treg cells with Treg/Teff disorder causes autoimmune diseases; however, the precise mechanisms are not thoroughly revealed. Here, we report that miR-34a could attenuate human and murine Foxp3 gene expression via targeting their 3′ untranslated regions (3′ UTR). The human miR-34a, increased in peripheral blood mononuclear cells (PBMCs) and CD4+ T cells from rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) patients, displayed a positive correlation with some serum markers of inflammation including rheumatoid factor (RF), anti-streptolysin antibody (ASO), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) as well as Th17 signature gene RORγt, but inversely correlated with the mRNA expression levels of FOXP3. In addition, murine miR-34a levels were downregulated in TGF-β-induced Treg cells but upregulated in Th17 cells induced in vitro compared to activated CD4+ T cells. It has also been demonstrated that elevated miR-34a disrupting Treg/Th17 balance in vivo contributed to the progress of pathogenesis of collagen induced arthritis (CIA) mice. Furthermore, IL-6 and TNF-α were responsible for the upregulation of miR-34a and downregulation of Foxp3, which was reverted by the addition of NF-κB/p65 inhibitor BAY11-7082, thus indicating that NF-κB/p65 inhibited Foxp3 expression in an miR-34a-dependent manner. Finally, IL-6 or TNF-α-activated p65 could bind to the miR-34a promotor and enhance its activity, resulting in upregulation of its transcription. Taken together, we show that NF-κB activated by inflammatory cytokines, such as IL-6 and TNF-α, ameliorates Foxp3 levels via regulating miR-34a expression, which provides a new mechanistic and therapeutic insight into the ongoing of autoimmune diseases.
UR - http://www.scopus.com/inward/record.url?scp=85068846078&partnerID=8YFLogxK
U2 - 10.1016/j.jaut.2019.04.018
DO - 10.1016/j.jaut.2019.04.018
M3 - Article
C2 - 31130368
AN - SCOPUS:85068846078
SN - 0896-8411
VL - 102
SP - 96
EP - 113
JO - Journal of Autoimmunity
JF - Journal of Autoimmunity
ER -